Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Impact · against what's priced in

Novartis faces a minor setback as it terminates a mid-stage trial for Fabhalta in a kidney condition. The impact is limited as it represents a failure in a specific indication rather than a systemic failure of the drug platform.

NVS−0.30: No priced-in read yet
In context: The discontinuation of the mid-stage Fabhalta trial for a serious kidney condition removes a potential growth catalyst for the drug's label expansion.
Read from the article alone

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

NVS
biopharma
clinical trial
drug development
kidney disease
novartis

Search tags

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

What matters in this story

How each ticker is affected

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

What matters in this story

How each ticker is affected

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Track these names every morning.

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

What matters in this story

How each ticker is affected

Next reads from the same story arc

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

What matters in this story

How each ticker is affected

Next reads from the same story arc

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Track these names every morning.

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady